CHE is a painful, inflammatory skin condition affecting up to 1 in 10 adults globally¹. It significantly impacts quality of life by interfering with daily activities and causing psychological distress^2-4. Delgocitinib, a steroid-free topical pan-Janus kinase (JAK) inhibitor, has demonstrated strong efficacy in two pivotal Phase 3 trials (DELTA 1 and 2) with significant skin clearance improvement and pain and itch relief compared to placebo⁵. Together with its favorable safety profile, these results have led to its FDA approval for adults with moderate-to-severe CHE. In parallel, the DELTA China Phase 3 trial aims to assess its efficacy in local populations, with findings expected to be published soon. As no approved treatments currently exist for moderate-to-severe CHE in China, this represents a significant and hopeful advancement for patients⁶.

References

1. Quaade AS, et al. Contact Dermatitis. 2021;84:361–374. 2. Grant L, et al. Adv Ther. 2020;37(2):692-706. 3. Dalgard FJ, et al. J Invest Dermatol. 2015;135(4):984-991. 4. Cortesi PA, et al. Contact Dermatitis. 2014;70(3):158-168.5. Bissonnette R, et al. Lancet. 2024;404:461-473. 6. NCT06004050. ClinicalTrials.gov. Accessible from: https://clinicaltrials.gov/study/NCT06004050. 7. Kato K, et al. NPJ Aging. 2025;11(1):55. 8. Hirano KI, Higashi M, Nakajima K. Eur Heart J. 2023 Apr 1;44(13):1191. 9. Qi J, et al. Nat Med. Published online July 2, 2025. doi:10.1038/s41591-025-03773-w. 10. Pryor JL, et al. J Strength Cond Res. 2024;38(7):1350-1357.